The short answer to our title question is that you present a clinical trial that’s a game-changer for treating metastatic breast cancer. That’s what happened in June when Shanu Modi, MD, medical oncologist and attending physician at Memorial Sloan Kettering Cancer Center, shared the results of the DESTINY-Breast04 trial at the American Society of Clinical Oncology meeting.
MSK’s Dr. Shanu Modi, principal investigator on the DESTINY-Breast04 trial, talks with the Our Metastatic Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
Thanks for listening!
More info about the show and past episodes is available on our website: www.ourmbclife.org
Got something to share? Feedback?
Email: ourmbclife@sharecancersupport.org
Follow us on Facebook, Instagram, and twitter @ourmbclife
The short answer to our title question is that you present a clinical trial that’s a game-changer for treating metastatic breast cancer. That’s what happened in June when Shanu Modi, MD, medical oncologist and attending physician at Memorial Sloan Kettering Cancer Center, shared the results of the DESTINY-Breast04 trial at the American Society of Clinical Oncology meeting.
MSK’s Dr. Shanu Modi, principal investigator on the DESTINY-Breast04 trial, talks with the Our Metastatic Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
Thanks for listening!
More info about the show and past episodes is available on our website: www.ourmbclife.org
Got something to share? Feedback?
Email: ourmbclife@sharecancersupport.org
Follow us on Facebook, Instagram, and twitter @ourmbclife